LymphedemaV1, Main, Exploration, bibRecord, 003662

Evaluating the efficacy of rBmHATαc as a multivalent vaccine against lymphatic filariasis in experimental animals and optimizing the adjuvant formulation

Identifieur interne : 003662 ( Main/Exploration ); précédent : 003661; suivant : 003663

Evaluating the efficacy of rBmHATαc as a multivalent vaccine against lymphatic filariasis in experimental animals and optimizing the adjuvant formulation

Auteurs : Gajalakshmi Dakshinamoorthy ; Ramaswamy Kalyanasundaram

Source :

Vaccine [ 0264-410X ] ; 2013.

RBID : PMC:3866973

Descripteurs français

KwdFr :
- Adjuvants immunologiques, Animaux, Anticorps antihelminthe (immunologie), Anticorps antihelminthe (sang), Antigènes d'helminthe (immunologie), Brugia malayi (génétique), Brugia malayi (immunologie), Filariose lymphatique (), Filariose lymphatique (immunologie), Immunisation, Immunoglobuline G (immunologie), Immunoglobuline G (sang), Modèles animaux de maladie humaine, Mâle, Protéines d'helminthes (génétique), Protéines d'helminthes (immunologie), Rate (immunologie), Souris, Spécificité des anticorps (immunologie), Vaccins (administration et posologie), Vaccins (immunologie).
MESH :
- administration et posologie : Vaccins.
- génétique : Brugia malayi, Protéines d'helminthes.
- immunologie : Anticorps antihelminthe, Antigènes d'helminthe, Brugia malayi, Filariose lymphatique, Immunoglobuline G, Protéines d'helminthes, Rate, Spécificité des anticorps, Vaccins.
- sang : Anticorps antihelminthe, Immunoglobuline G.
- Adjuvants immunologiques, Animaux, Filariose lymphatique, Immunisation, Modèles animaux de maladie humaine, Mâle, Souris.

English descriptors

KwdEn :
- Adjuvants, Immunologic, Animals, Antibodies, Helminth (blood), Antibodies, Helminth (immunology), Antibody Specificity (immunology), Antigens, Helminth (immunology), Brugia malayi (genetics), Brugia malayi (immunology), Disease Models, Animal, Elephantiasis, Filarial (immunology), Elephantiasis, Filarial (prevention & control), Helminth Proteins (genetics), Helminth Proteins (immunology), Immunization, Immunoglobulin G (blood), Immunoglobulin G (immunology), Male, Mice, Spleen (immunology), Vaccines (administration & dosage), Vaccines (immunology).
MESH :
- chemical , administration & dosage : Vaccines.
- chemical , blood : Antibodies, Helminth, Immunoglobulin G.
- chemical , genetics : Helminth Proteins.
- chemical , immunology : Antibodies, Helminth, Antigens, Helminth, Helminth Proteins, Immunoglobulin G, Vaccines.
- chemical : Adjuvants, Immunologic.
- genetics : Brugia malayi.
- immunology : Antibody Specificity, Brugia malayi, Elephantiasis, Filarial, Spleen.
- prevention & control : Elephantiasis, Filarial.
- Animals, Disease Models, Animal, Immunization, Male, Mice.

Abstract

Developing an effective vaccine against lymphatic filariasis will complement the WHO's effort to eradicate the infection from endemic areas. Currently 83 different countries are endemic for this infection and over 1 billion people are at risk. An effective vaccine coupled with mass drug administration will reduce the morbidity and social stigma associated with this gruesome disease. Several potential vaccine candidates that can confer partial protection in experimental animals have been reported from different laboratories. However, no licensed vaccines are currently available for this disease. Among the several vaccine antigens identified from our laboratory, three most promising antigens; rBmHSPαc (α crystalline domain and c-terminal extension of Heat Shock Protein 12.6), rBmALT-2 (Abundant larval transcript) and rBmTSP LEL (Tetraspanin large extracellular loop) was further developed as a recombinant fusion protein vaccine (rBmHATαc). In a mouse model this fusion protein vaccine gave close to 68% protection following a challenge infection. To improve the vaccine efficiency of rBmHATαc, in this study we evaluated various preparations of alum (AL007, AL019, Alhydrogel and Imject® Alum) as adjuvants. Our results show that mice immunized with rBmHATαc formulated in AL007 (alum from IDRI) and/or AL019 (alum plus TLR-4 agonist from IDRI) gave the highest IgG antibody titer compared to other groups. Subsequent in vivo challenge experiments confirmed that >95% protection can be achieved when AL007 or AL019 was used as the adjuvant. However, when Imject® Alum or alhydrogel was used as the adjuvant only 76% and 72% protection respectively could be achieved. These results show that AL007 or AL019 (IDRI) is an excellent choice of adjuvant for the rBmHATαc vaccine against B. malayi L3 in mice.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3866973

DOI: 10.1016/j.vaccine.2013.10.083
PubMed: 24211167
PubMed Central: 3866973

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Evaluating the efficacy of r<italic>Bm</italic>
HATαc as a multivalent vaccine against lymphatic filariasis in experimental animals and optimizing the adjuvant formulation</title>
<author><name sortKey="Dakshinamoorthy, Gajalakshmi" sort="Dakshinamoorthy, Gajalakshmi" uniqKey="Dakshinamoorthy G" first="Gajalakshmi" last="Dakshinamoorthy">Gajalakshmi Dakshinamoorthy</name>
</author>
<author><name sortKey="Kalyanasundaram, Ramaswamy" sort="Kalyanasundaram, Ramaswamy" uniqKey="Kalyanasundaram R" first="Ramaswamy" last="Kalyanasundaram">Ramaswamy Kalyanasundaram</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">24211167</idno>
<idno type="pmc">3866973</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3866973</idno>
<idno type="RBID">PMC:3866973</idno>
<idno type="doi">10.1016/j.vaccine.2013.10.083</idno>
<date when="2013">2013</date>
<idno type="wicri:Area/Pmc/Corpus">003798</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">003798</idno>
<idno type="wicri:Area/Pmc/Curation">003797</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">003797</idno>
<idno type="wicri:Area/Pmc/Checkpoint">002347</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">002347</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">001848</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001848</idno>
<idno type="wicri:Area/PubMed/Curation">001848</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001848</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001848</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001848</idno>
<idno type="wicri:Area/Ncbi/Merge">005F10</idno>
<idno type="wicri:Area/Ncbi/Curation">005F10</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">005F10</idno>
<idno type="wicri:doubleKey">0264-410X:2013:Dakshinamoorthy G:evaluating:the:efficacy</idno>
<idno type="wicri:Area/Main/Merge">003669</idno>
<idno type="wicri:Area/Main/Curation">003662</idno>
<idno type="wicri:Area/Main/Exploration">003662</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Evaluating the efficacy of r<italic>Bm</italic>
HATαc as a multivalent vaccine against lymphatic filariasis in experimental animals and optimizing the adjuvant formulation</title>
<author><name sortKey="Dakshinamoorthy, Gajalakshmi" sort="Dakshinamoorthy, Gajalakshmi" uniqKey="Dakshinamoorthy G" first="Gajalakshmi" last="Dakshinamoorthy">Gajalakshmi Dakshinamoorthy</name>
</author>
<author><name sortKey="Kalyanasundaram, Ramaswamy" sort="Kalyanasundaram, Ramaswamy" uniqKey="Kalyanasundaram R" first="Ramaswamy" last="Kalyanasundaram">Ramaswamy Kalyanasundaram</name>
</author>
</analytic>
<series><title level="j">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
<idno type="eISSN">1873-2518</idno>
<imprint><date when="2013">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic</term>
<term>Animals</term>
<term>Antibodies, Helminth (blood)</term>
<term>Antibodies, Helminth (immunology)</term>
<term>Antibody Specificity (immunology)</term>
<term>Antigens, Helminth (immunology)</term>
<term>Brugia malayi (genetics)</term>
<term>Brugia malayi (immunology)</term>
<term>Disease Models, Animal</term>
<term>Elephantiasis, Filarial (immunology)</term>
<term>Elephantiasis, Filarial (prevention & control)</term>
<term>Helminth Proteins (genetics)</term>
<term>Helminth Proteins (immunology)</term>
<term>Immunization</term>
<term>Immunoglobulin G (blood)</term>
<term>Immunoglobulin G (immunology)</term>
<term>Male</term>
<term>Mice</term>
<term>Spleen (immunology)</term>
<term>Vaccines (administration & dosage)</term>
<term>Vaccines (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques</term>
<term>Animaux</term>
<term>Anticorps antihelminthe (immunologie)</term>
<term>Anticorps antihelminthe (sang)</term>
<term>Antigènes d'helminthe (immunologie)</term>
<term>Brugia malayi (génétique)</term>
<term>Brugia malayi (immunologie)</term>
<term>Filariose lymphatique ()</term>
<term>Filariose lymphatique (immunologie)</term>
<term>Immunisation</term>
<term>Immunoglobuline G (immunologie)</term>
<term>Immunoglobuline G (sang)</term>
<term>Modèles animaux de maladie humaine</term>
<term>Mâle</term>
<term>Protéines d'helminthes (génétique)</term>
<term>Protéines d'helminthes (immunologie)</term>
<term>Rate (immunologie)</term>
<term>Souris</term>
<term>Spécificité des anticorps (immunologie)</term>
<term>Vaccins (administration et posologie)</term>
<term>Vaccins (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Helminth</term>
<term>Immunoglobulin G</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Helminth Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Helminth</term>
<term>Antigens, Helminth</term>
<term>Helminth Proteins</term>
<term>Immunoglobulin G</term>
<term>Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Adjuvants, Immunologic</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Brugia malayi</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Brugia malayi</term>
<term>Protéines d'helminthes</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antihelminthe</term>
<term>Antigènes d'helminthe</term>
<term>Brugia malayi</term>
<term>Filariose lymphatique</term>
<term>Immunoglobuline G</term>
<term>Protéines d'helminthes</term>
<term>Rate</term>
<term>Spécificité des anticorps</term>
<term>Vaccins</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Antibody Specificity</term>
<term>Brugia malayi</term>
<term>Elephantiasis, Filarial</term>
<term>Spleen</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Elephantiasis, Filarial</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antihelminthe</term>
<term>Immunoglobuline G</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Disease Models, Animal</term>
<term>Immunization</term>
<term>Male</term>
<term>Mice</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adjuvants immunologiques</term>
<term>Animaux</term>
<term>Filariose lymphatique</term>
<term>Immunisation</term>
<term>Modèles animaux de maladie humaine</term>
<term>Mâle</term>
<term>Souris</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p id="P1">Developing an effective vaccine against lymphatic filariasis will complement the WHO's effort to eradicate the infection from endemic areas. Currently 83 different countries are endemic for this infection and over 1 billion people are at risk. An effective vaccine coupled with mass drug administration will reduce the morbidity and social stigma associated with this gruesome disease. Several potential vaccine candidates that can confer partial protection in experimental animals have been reported from different laboratories. However, no licensed vaccines are currently available for this disease. Among the several vaccine antigens identified from our laboratory, three most promising antigens; r<italic>Bm</italic>
HSPαc (α crystalline domain and c-terminal extension of Heat Shock Protein 12.6), r<italic>Bm</italic>
ALT-2 (Abundant larval transcript) and r<italic>Bm</italic>
TSP LEL (Tetraspanin large extracellular loop) was further developed as a recombinant fusion protein vaccine (r<italic>Bm</italic>
HATαc). In a mouse model this fusion protein vaccine gave close to 68% protection following a challenge infection. To improve the vaccine efficiency of r<italic>Bm</italic>
HATαc, in this study we evaluated various preparations of alum (AL007, AL019, Alhydrogel and Imject® Alum) as adjuvants. Our results show that mice immunized with r<italic>Bm</italic>
HATαc formulated in AL007 (alum from IDRI) and/or AL019 (alum plus TLR-4 agonist from IDRI) gave the highest IgG antibody titer compared to other groups. Subsequent <italic>in vivo</italic>
 challenge experiments confirmed that >95% protection can be achieved when AL007 or AL019 was used as the adjuvant. However, when Imject® Alum or alhydrogel was used as the adjuvant only 76% and 72% protection respectively could be achieved. These results show that AL007 or AL019 (IDRI) is an excellent choice of adjuvant for the r<italic>Bm</italic>
HATαc vaccine against <italic>B. malayi</italic>
 L3 in mice.</p>
</div>
</front>
</TEI>
<affiliations><list></list>
<tree><noCountry><name sortKey="Dakshinamoorthy, Gajalakshmi" sort="Dakshinamoorthy, Gajalakshmi" uniqKey="Dakshinamoorthy G" first="Gajalakshmi" last="Dakshinamoorthy">Gajalakshmi Dakshinamoorthy</name>
<name sortKey="Kalyanasundaram, Ramaswamy" sort="Kalyanasundaram, Ramaswamy" uniqKey="Kalyanasundaram R" first="Ramaswamy" last="Kalyanasundaram">Ramaswamy Kalyanasundaram</name>
</noCountry>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003662 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003662 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     PMC:3866973
   |texte=   Evaluating the efficacy of rBmHATαc as a multivalent vaccine against lymphatic filariasis in experimental animals and optimizing the adjuvant formulation
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:24211167" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

Serveur d'exploration sur le lymphœdème

Evaluating the efficacy of rBmHATαc as a multivalent vaccine against lymphatic filariasis in experimental animals and optimizing the adjuvant formulation

Evaluating the efficacy of rBmHATαc as a multivalent vaccine against lymphatic filariasis in experimental animals and optimizing the adjuvant formulation

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.